JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $427 from $415 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $400 from $350 at Oppenheimer
- Paulson takes new stake in Southwestern Energy, exits AngloGold Ashanti
- Madrigal Pharmaceuticals price target raised to $236 from $194 at B. Riley
- Biotech Alert: Searches spiking for these stocks today
- Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH